The amount of investments in joint ventures in an entity's separate financial statements. [Refer: Joint ventures [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2021-01-01
-Paragraph 10
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_InvestmentsInJointVentures
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 50
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_a&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_UndrawnBorrowingFacilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amounts payable partners in collaboration agreements.

+ References

No definition available.

+ Details

Name:	sny_AmountsPayablePartnersInCollaborationAgreements
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments Received For Development Costs

+ References

No definition available.

+ Details

Name:	sny_CommitmentsReceivedForDevelopmentCosts
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments Related To Collaboration, Discovery, Development And Commercialization Agreements

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments Related To Maximum Payments For Projects Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Commitments Related To Milestone Payments For Projects Under Collaboration Agreements

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments related to r and d payments contingent upon attainment of sales targets.

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments Related To Research And Development Relating To Projects In Research Phase

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contingent Consideration Collaboration Agreements

+ References

No definition available.

+ Details

Name:	sny_ContingentConsiderationCollaborationAgreements
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Cumulative Development Costs Incurred

+ References

No definition available.

+ Details

Name:	sny_CumulativeDevelopmentCostsIncurred
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number Of Immunology Or Inflammation Targets Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Novel Small Molecule Candidates To Be Developed Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Oncology Targets Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_NumberOfOncologyTargetsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Targets That Encompass All Diseases Areas

+ References

No definition available.

+ Details

Name:	sny_NumberOfTargetsThatEncompassAllDiseasesAreas
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Off Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments

+ References

No definition available.

+ Details

Name:	sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Percentage of cumulative development costs reimbursed.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix:	sny_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of future development expense funded by company.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfFutureDevelopmentExpenseFundedByCompany
Namespace Prefix:	sny_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of future development expense funded by other party.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty
Namespace Prefix:	sny_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of profit share on counter parties profit.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix:	sny_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Provisions and other non-current liabilities.

+ References

No definition available.

+ Details

Name:	sny_ProvisionsAndOtherNonCurrentLiabilitiesLineItems
Namespace Prefix:	sny_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Reserve percentage of pandemic vaccines.

+ References

No definition available.

+ Details

Name:	sny_ReservePercentageOfPandemicVaccines
Namespace Prefix:	sny_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Share of operating expenses and cost of producion to joint partner payable period.

+ References

No definition available.

+ Details

Name:	sny_ShareOfOperatingExpensesAndCostOfProductionToJointPartnerPayablePeriod
Namespace Prefix:	sny_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Transfer percentage of pandemic vaccines.

+ References

No definition available.

+ Details

Name:	sny_TransferPercentageOfPandemicVaccines
Namespace Prefix:	sny_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Upfront payments.

+ References

No definition available.

+ Details

Name:	sny_UpfrontPayments
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_AblynxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_KymabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=sny_WorldHealthOrganizationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_DiceMoleculesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_LonzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_ABLBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_AdageneIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_BlackstoneLifeSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_IGMBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_SkyhawkTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_MiReculeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_InnatePharmaSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_ExscientiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_AtomwiseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_ScribeTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_InsilicoMedicineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Off balance sheet commitments - Additional Information (Details) € in Millions, $ in Millions													3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 19, 2022 USD ($)	Nov. 08, 2022 USD ($)	Oct. 04, 2022 USD ($)	Sep. 27, 2022 USD ($)	Aug. 17, 2022 USD ($)	Jul. 05, 2022 USD ($)	Mar. 29, 2022 USD ($)	Mar. 15, 2022 EUR (€)	Mar. 02, 2022 USD ($)	Jan. 11, 2022 USD ($)	Jan. 07, 2022 USD ($) molecule	Feb. 27, 2017 EUR (€)	Mar. 31, 2022	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2016 target	Dec. 31, 2022 EUR (€)	Mar. 29, 2022 EUR (€) target	Dec. 31, 2021 EUR (€)	Apr. 08, 2021 USD ($)	Dec. 31, 2020 EUR (€)	Feb. 28, 2014
Provisions and other non-current liabilities [Line Items]
Commitments related to research and development relating to projects in research phase \| €																	€ 18,000		€ 6,700
Commitments related to research and development payments contingent upon attainment of sales targets \| €																	18,500		8,100
Commitments related to collaboration, discovery, development and commercialization agreements \| €																	8,800		5,800
Commitments related to attainment of regulatory and sales milestones for commercialized products \| €																	7,600		4,200
Cumulative development costs incurred \| €																			8,400
Total credit facilities \| €																	8,000		8,000		€ 8,000
Commitments received in respect of disposals proceeds receivable and contingent consideration on divestments														$ 1,000.0	$ 1,000.0
Sanofi Belgium
Provisions and other non-current liabilities [Line Items]
Commitments related to collaboration, discovery, development and commercialization agreements \| €																	1,000		1,000
Kymab
Provisions and other non-current liabilities [Line Items]
Commitments related to collaboration, discovery, development and commercialization agreements \| €																	200		500
Commitments related to milestone payments for projects under collaboration agreements																				$ 350.0
World Health Organization
Provisions and other non-current liabilities [Line Items]
Percentage of pandemic vaccines agreed to transfer																						7.50%
Percentage of pandemic vaccines agreed to reserve																						7.50%
Joint ventures
Provisions and other non-current liabilities [Line Items]
Percentage of future development expense funded by other party												5000.00%
Dice Molecules
Provisions and other non-current liabilities [Line Items]
Targets that encompass all diseases areas \| target																12
Lonza \| Joint ventures
Provisions and other non-current liabilities [Line Items]
Investments in joint ventures \| €												€ 300
Percentage of future development expense funded by company												50.00%
Amounts payable partners in collaboration agreements \| €												€ 600
Share of operating expenses and cost of production to joint partner payable period												15 years
ABL Bio
Provisions and other non-current liabilities [Line Items]
Upfront payment										$ 75.0
ABL Bio \| Maximum
Provisions and other non-current liabilities [Line Items]
Commitments related to milestone payments for projects under collaboration agreements										$ 985.0
Adagene, Inc
Provisions and other non-current liabilities [Line Items]
Upfront payment									$ 17.5
Adagene, Inc \| Maximum
Provisions and other non-current liabilities [Line Items]
Commitments related to milestone payments for projects under collaboration agreements									$ 2,500.0
Blackstone Life Sciences \| Antibodies collaboration agreement
Provisions and other non-current liabilities [Line Items]
Commitments related to maximum payments for projects under collaboration agreement \| €								€ 300
IGM Biosciences, Inc
Provisions and other non-current liabilities [Line Items]
Upfront payment							$ 150.0
IGM Biosciences, Inc \| Maximum
Provisions and other non-current liabilities [Line Items]
Number of oncology targets under collaboration agreement \| target																		3
Number of immunology or inflammation targets under collaboration agreement \| target																		3
Contingent consideration collaboration agreements \| €																		€ 6,000
Skyhawk Therapeutics, Inc
Provisions and other non-current liabilities [Line Items]
Upfront payment						$ 54.0
Skyhawk Therapeutics, Inc \| Maximum
Provisions and other non-current liabilities [Line Items]
Contingent consideration collaboration agreements						$ 2,000.0
miRecule
Provisions and other non-current liabilities [Line Items]
Upfront payment			$ 20.0
miRecule \| Maximum
Provisions and other non-current liabilities [Line Items]
Contingent consideration collaboration agreements			$ 400.0
Innate Pharma SA
Provisions and other non-current liabilities [Line Items]
Upfront payment	$ 25.0
Innate Pharma SA \| Maximum
Provisions and other non-current liabilities [Line Items]
Contingent consideration collaboration agreements	$ 1,400.0
Exscientia
Provisions and other non-current liabilities [Line Items]
Upfront payment											$ 100.0
Exscientia \| Maximum
Provisions and other non-current liabilities [Line Items]
Number of novel small molecule candidates developed \| molecule											15
Commitments related to milestone payments for projects under collaboration agreements											$ 5,200.0
Atomwise
Provisions and other non-current liabilities [Line Items]
Upfront payment					$ 20.0
Atomwise \| Maximum
Provisions and other non-current liabilities [Line Items]
Contingent consideration collaboration agreements					$ 1,000.0
Scribe Therapeutics
Provisions and other non-current liabilities [Line Items]
Upfront payment				$ 25.0
Scribe Therapeutics \| Maximum
Provisions and other non-current liabilities [Line Items]
Contingent consideration collaboration agreements				$ 1,000.0
Insilico Medicine
Provisions and other non-current liabilities [Line Items]
Upfront payment		$ 12.5
Insilico Medicine \| Maximum
Provisions and other non-current liabilities [Line Items]
Contingent consideration collaboration agreements		$ 1,200.0
Regeneron Pharmaceuticals, INC \| Antibodies collaboration agreement
Provisions and other non-current liabilities [Line Items]
Commitments received for development costs \| €																	€ 2,700		€ 2,900
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)													10.00%	20.00%
Percentage of cumulative development costs reimbursed															50.00%